Search Site

Trends banner

ADNOC Drilling H1 revenue $2.37bn

The company posted a net profit of $692m.

Eni profit falls due to dip in oil prices

Q2 net profit fell by 18% to $637 million.

Emirates NBD H1 profit $3.40bn

Total income rose by 12 percent in the same period.

ADIB H1 pre-tax profit $1.08bn

Q2 pre-tax net profit increases by 14 percent.

AstraZeneca to invest $50bn in US

Bulk of funds to go into a Virginia manufacturing center.

Saudi professor secures US patent for innovative cancer therapy

Saudi professor secures US patent for immune cell-stimulating cancer innovation. File pic
  • The patent describes the development of a modern technology that targets an immune protein with a high concentration on the surface of immune system cells
  • The protein targeted in this project is called CRACC, and theresearch has demonstrated that CRACC protein exists on the surface of immune system cells in cancers

Washington, USA — The Saudi faculty member at Michigan State University Dr. Yasser Al-Dhamin, received a patent from the US Patent Office for an innovation that stimulates the functioning of immune cells within cancer blocks and increases the effectiveness of vaccines.

In a statement to the Saudi Press Agency (SPA), Al-Dhamin said: “The current patent describes the development of a modern technology that targets an immune protein with a high concentration on the surface of immune system cells in chronic cases, such as cancer and exposure to specific microbes, such as HIV, malaria parasite, and bacteria that cause tuberculosis, causing chronic diseases.”

He added: “The protein targeted in this project is called CRACC, and our research has demonstrated that CRACC protein exists at a high concentration on the surface of immune system cells in cancers. This protein inhibits the functioning of immune system cells that helps the spread of cancer.”

Al-Dhamin continued: “To translate this discovery for immunotherapy and to demonstrate that inhibiting the action of the CRACC protein stimulates the cells of the immune system against cancer, we have developed an immune protein called CRACC-Fc Fusion protein, which inhibits the CRACC protein within the immune system cells in cancer mass,” stressing that his published research has proven the efficiency of the CRACC-Fc Fusion protein and its ability to stimulate immune cells.

He also said that he used CRACC-Fc Fusion protein with vaccines directed against colon cancer (Ad5-CEA + CRACC-Fc) and against the acquired immune virus (Ad5-HIV/Gap + CRACC-FC) and proved its ability to increase vaccine efficiency.

Al-Dhamin is the deputy director of research at the university’s faculty of medicine.